1. Berger D: DOUBLE-BLINDING AND BIAS IN MEDICATION AND COGNITIVE-BEHAVIORAL THERAPY TRIALS FOR MAJOR DEPRESSIVE DISORDER, F1000Research 2015, 4:638 (doi: 10.12688/f1000research.6953.1)
  2. Berger D: DOUBLE BLINDING REQUIREMENT FOR VALIDITY CLAIMS IN COGNITIVE-BEHAVIORAL THERAPY INTERVENTION TRIALS FOR MAJOR DEPRESSIVE DISORDER. Analysis of Hollon S, et al., Effect of cognitive therapy with antidepressant medications vs antidepressants alone on the rate of recovery in major depressive disorder: a randomized clinical trial, F1000Research 2015, 4:639 (doi: 10.12688/f1000research.6954.1)
  3. Berger D: TESTS, TESTING, AND TESTED -WE NEED TO CRITICALLY EVALUATE THE MEANING OF TESTS IN PSYCHIATRY, Indian Journal of Psychiatry, 2013;55:200-3.
  4. Berger D: AN EPIDEMIC OF DEPRESSIONPsychiatric Times, (Letter) 26:6, May 12, 2009.
  5. Berger D, Eames D, Prados-Ruano P: MENTAL HEALTH CARE OF WESTERN EXPATRIATES IN TOKYOTravel Medicine and Infectious Disease, 6:5, 321-325, September 2008.
  6. Berger D: ROLE OF COGNITIVE THERAPY IN DEPRESSION TREATMENT,
    Psychiatric Times, (Letter) 25:7, June, p.78; 2008.
  7. Berger D: METHODOLOGIC ISSUES IN THE CLINICAL TRIAL STUDY OF DEPRESSION, Pharma Japan, 2083; 18-19. March 24, 2008.
  8. Berger D: DEFENSES CAN SABOTAGE THE THERAPY,
    Psychiatric Times, 12:12, 23-27, Special Edition, October 2005.
  9. Berger D: ANTIDEPRESSANT DRUG DEVELOPENT IN JAPAN: CURRENT PERSPECTIVES AND FUTURE HORIZONS, Clinical Research Focus, 16:7, 32-35, Sept 2005.
  10. Berger D, Fukunishi I, Wogan J, Kuboki T: ALEXITHYMIC TRAITS AS PREDICTORS OF DIFFICULTIES WITH ADJUSTMENT IN AN OUTPATIENT COHORT OF EXPATRIATES IN TOKYO,Psychological Reports , 85:67-77;1999.
Advertisements